Program
Linagliptin
Also written as “BI 1356”, “linagliptin” and “Linagliptin/Metformin FDC”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Esophageal Neoplasms · Carcinoma, Non-Small-Cell Lung · Hypertension, led by 7 companies.
Drug pageLinagliptin: every studyMany companies study it; this page follows only the 89 they lead. All 129 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 800 open or running | phase 4since Sep 21, 2011 | Mar 31, 2006 | none ahead |
| Dong Wha Pharmaceutical | 30 open or running | phase 1since Aug 6, 2014 | Aug 6, 2014 | none ahead |
| Profil Institut für Stoffwechselforschungits history only | 20 open or running | phase 4since Jul 11, 2013 | Jul 11, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Aug 3, 2016 | Aug 3, 2016 | none ahead |
| ikfe-CROits history only | 10 open or running | phase 3since Feb 11, 2015 | Feb 11, 2015 | none ahead |
| Marcus Borchertits history only | 10 open or running | phase 4since Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Nabiqasim Industries (Pvt)its history only | 11 open or running | phase 4since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: Halozyme Therapeutics, BioLineRx, Eli Lilly, Eva Pharma, Ikfe and MLM Medical Labs.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dong Wha Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2014First study: phase 1 study in HealthyFirst studyNCT02212782 · 12 enrolled · Korea, Republic of
- Apr 6, 20232 phase 1 studies in Healthy SubjectsNCT05874180, NCT05874167
TargetBeta
“A potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
All 3 Dong Wha Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05874180Healthy Subjects · Korea, Republic of | 1 | Completed | Feb 1, 2023 | 31 |
| NCT05874167Healthy Subjects · Korea, Republic of | 1 | Completed | Oct 11, 2022 | 50 |
| NCT02212782Healthy · Korea, Republic of | 1 | Completed | Nov 2014 | 12 |
How it is read
Names in the registry
- “Linagliptin”, 35 entries
- “BI 1356”, 14 entries
- “linagliptin”, 10 entries
- “Linagliptin/Metformin FDC”, 4 entries
- “BI 1356 BS”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 46 studies
- Diabetes Mellitus, 2 studies
- Esophageal Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.